India, July 1 -- Urteste S.A. (URT.WA), a cancer diagnostics company, on Wednesday reported receiving a patent from the U.S. Patent and Trademark Office (U.S. PTO) for the proprietary Panuri test developed for pancreatic cancer.
Pancreatic cancer remains one of the most late-diagnosed cancers in the world, with highly unpredictable prognoses.
The Panuri test was previously awarded parents in Poland, Japan, Indonesia, Singapore, Russia, and South Korea.
The test was designed to detect malignancies through a simple urine analysis and was recently administered to the first participant in a clinical trial on June 10, 2026 in Europe. The study is expected to evaluate about 550 samples across 30 centres in Poland and Hungary, with a primary en...